<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879928</url>
  </required_header>
  <id_info>
    <org_study_id>FM101-CTP1-001</org_study_id>
    <nct_id>NCT03879928</nct_id>
  </id_info>
  <brief_title>A SAD, MAD, and FE Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of FM101 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Alternating Panel Single Ascending Dose, Sequential Multiple Ascending Dose, and Food Effect Study of FM101 in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Future Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Future Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a double blind, randomized, placebo controlled, single and multiple ascending dose
      (SAD/MAD) study in healthy subjects. Safety evaluation will include adverse events (TEAEs),
      clinical laboratory values, vital signs, ECGs, and physical examinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study in healthy volunteers designed
      to assess the safety, tolerability and PK of FM101. This study will consist of 3 parts: a SAD
      part, a single dose FE part and a MAD part. Each subject is to participate in only 1 part of
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of FM101 after SAD and MAD doses to healthy volunteers by assessing the number, severity, and type of TEAEs.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of TEAEs (frequency of occurrence, number of subjects experiencing the event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in clinical laboratory values from the baseline after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in vital signs from the baseline after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in electrocardiograms (ECGs) after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the change in physical examinations after SAD and MAD doses.</measure>
    <time_frame>SAD [Day 1 through Day 7], MAD [Day 1 through Day 10]</time_frame>
    <description>The number of abnormalities with clinical significance (frequency of occurrence, number of subjects experiencing the event).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess maximum observed plasma concentration (Cmax) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Cmax of FM101 in plasma will be calculated as applicable:
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess area under plasma concentration-time curve from hour 0 to last sample following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>AUClast of FM101 in plasma will be calculated as applicable:
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess area under plasma concentration-time curve from hour 0 to infinity following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>AUCinf of FM101 in plasma will be calculated as applicable:
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess time to reach the maximum concentration in plasma (Tmax) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Tmax of FM101 in plasma will be calculated as applicable:
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess terminal elimination rate constant (Kel) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Kel of FM101 in plasma will be calculated as applicable:
SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess terminal half-life (t1/2) following SAD and MAD doses</measure>
    <time_frame>SAD phase - Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 36, 48, and 72 hours. MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>t1/2 of FM101 in plasma will be calculated as applicable: SAD phase - cohort 1 to 6 , MAD phase - cohort 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma Cmax of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>Cmax of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma AUClast of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>AUClast of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma AUCinf of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>AUCinf of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma Tmax of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>Tmax of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma Kel of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>Kel of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of food on the plasma t1/2 of FM101 after a single dose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>t1/2 of FM101 under fasted and fed conditions will be calculated after a single dose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urine concentrations of FM101 in MAD cohort 2</measure>
    <time_frame>MAD phase - At pre-dose (within 12 hours prior to dosing), and over 0-6, 6-12, 12-18, and 18-24 hours post-dose collection intervals on Day 1 and Day 7.</time_frame>
    <description>Cmax of FM101 in the urine will be calculated. MAD phase - cohort 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine concentrations of M6, FM101's metabolite in MAD cohort 2</measure>
    <time_frame>MAD phase - At pre-dose (within 12 hours prior to dosing), and over 0-6, 6-12, 12-18, and 18-24 hours post-dose collection intervals on Day 1 and Day 7.</time_frame>
    <description>Cmax of M6 in the urine will be calculated. MAD phase - cohort 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations of M6 in MAD cohort 2</measure>
    <time_frame>MAD phase - Day 1 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours after the first dose. Day 3 to Day 7 at pre-dose, 1, 2, 4, 6, 8, 12, and 24 hours.</time_frame>
    <description>Cmax of the plasma M6 will be calculated. MAD phase - cohor 2</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single and multiple ascending doses of FM101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FM101 for SAD</intervention_name>
    <description>The study drug (FM101) will be administered orally as SAD doses</description>
    <arm_group_label>FM101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for SAD</intervention_name>
    <description>The study drug (placebo) will be administered orally as SAD doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FM101 for MAD</intervention_name>
    <description>The study drug (FM101) will be administered orally as MAD doses</description>
    <arm_group_label>FM101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MAD</intervention_name>
    <description>The study drug (placebo) will be administered orally as MAD doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: male or female

          -  Age: 18 - 50 years, inclusive, at screening

          -  Body mass index (BMI) : 18.0 - 32.0 kg/m2 (inclusive)

          -  Weight : â‰¥ 50 kg

          -  Status : healthy subjects

          -  At screening, females must be non-pregnant and non-lactating, or of non child-bearing
             potential (either surgically sterilized or physiologically incapable of becoming
             pregnant, or at least 1 year post menopausal [amenorrhea duration of 12 consecutive
             months); non-pregnancy will be confirmed for all females by a serum pregnancy test
             conducted at screening, and a urine pregnancy test at each admission and at follow-up.

          -  Female subjects of child-bearing potential, with a fertile male sexual partner, must
             agree to use adequate contraception from screening until 90 days after the follow up
             visit. Adequate contraception is defined as using hormonal contraceptives or an
             intrauterine device combined with at least 1 of the following forms of contraception:
             a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with
             the lifestyle of the subject, is acceptable.

          -  Male subjects, if not surgically sterilized, must agree to use adequate contraception
             and not donate sperm from first admission to the clinical research center until 90
             days after the follow-up visit. Adequate contraception for the male subject (and his
             female partner) is defined as using hormonal contraceptives or an intrauterine device
             combined with at least 1 of the following forms of contraception: a diaphragm or
             cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of
             the subject is acceptable.

          -  All prescribed medication must have been stopped at least 14 days prior to (each)
             admission to the clinical research center. An exception is made for hormonal
             contraceptives, which may be used throughout the study.

          -  All over-the-counter medication, vitamin preparations and other food supplements, or
             herbal medications (eg, St. John's Wort) must have been stopped at least 7 days prior
             to (each) admission to the clinical research center. An exception is made for
             paracetamol, which is allowed up to admission to the clinical research center.

          -  Ability and willingness to abstain from alcohol, methylxanthine-containing beverages
             or food (coffee, tea, cola, chocolate, energy drinks), grapefruit (juice), and tobacco
             products from 48 hours prior to (each) admission to the clinical research center.

          -  Good physical and mental health on the basis of medical history, physical examination,
             clinical laboratory, ECG, and vital signs, as judged by the Investigator.

          -  Willing and able to sign the ICF.

        Exclusion Criteria:

          -  Employee of CRO or the Sponsor.

          -  History of relevant drug and/or food allergies.

          -  Using tobacco products within 60 days prior to (the first) drug administration.

          -  History of alcohol abuse or drug addiction (including soft drugs like cannabis
             products).

          -  Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including
             ecstasy], cannabinoids, barbiturates, benzodiazepines, gamma hydroxybutyric acid
             [GHB], tricyclic antidepressants, and alcohol) at screening and (each) admission to
             the clinical research center.

          -  Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals
             approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).

          -  Positive screen for hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV)
             antibodies, or anti human immunodeficiency virus (HIV) 1 and 2 antibodies.

          -  Participation in a drug study within 60 days prior to (the first) drug administration
             in the current study. Participation in more than 3 other drug studies (for male
             subjects) / more than 2 other drug studies (for female subjects) in the 10 months
             prior to (the first) drug administration in the current study.

          -  Donation or loss of more than 100 mL of blood within 60 days prior to (the first) drug
             administration. Donation or loss of more than 1.5 liters of blood (for male subjects)
             / more than 1.0 liters of blood (for female subjects) in the 10 months prior to (the
             first) drug administration in the current study.

          -  Significant and/or acute illness within 5 days prior to (the first) drug
             administration that may impact safety assessments, in the opinion of the Investigator.

          -  Non-willingness to consume the high-fat breakfast (Part B only).

          -  Unsuitable veins for infusion or blood sampling.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WanSeok Jeong, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Future Medicine Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renger Tiessen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seonah Ha, Ph.D</last_name>
    <phone>82222898690</phone>
    <email>hsa387@futuremedicine.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiyeon Kang, MS</last_name>
    <phone>82222898687</phone>
    <email>jykang@futuremedicine.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PRA health Sciences</name>
      <address>
        <city>Groningen</city>
        <state>Gn</state>
        <zip>9728NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renger G Tiessen, Ph.D</last_name>
      <email>TiessenRenger@prahs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

